

PRODUCT	DISEASE	PIPELINE			
		PHASE 1	PHASE 2	PHASE 3	COMMERCIAL
<b>TTR</b>					
<b>ONPATTRO®</b> (patisiran)	hATTR Amyloidosis with Polyneuropathy				
<b>AMVUTTRA®</b> (vutrisiran)	ATTR Amyloidosis with Cardiomyopathy and hATTR Amyloidosis with Polyneuropathy				
<b>Nucresiran</b> (ALN-TTRsc04)	ATTR Amyloidosis				
<b>RARE</b>					
<b>GIVLAARI®</b> (givosiran)	Acute Hepatic Porphyria (AHP)				
<b>OXLUMO®</b> (lumasiran)	Primary Hyperoxaluria Type 1 (PH1)				
<b>Qfitlia™</b> (fitusiran)	Hemophilia A or B <sup>1</sup>				
<b>Cemdisiran</b> (+/- Pozelimab)	Myasthenia Gravis <sup>1</sup>				
<b>Cemdisiran</b> (+ Pozelimab)	Paroxysmal Nocturnal Hemoglobinuria <sup>1</sup>				
<b>ALN-6400</b>	Bleeding Disorders				
<b>CARDIOVASCULAR</b>					
<b>Leqvio®</b> (inclisiran)	Hypercholesterolemia <sup>1</sup>				
<b>Zilebesiran</b>	Hypertension <sup>2</sup>				
<b>Zilebesiran + REVERSIR</b>	Hypertension <sup>2</sup>				
<b>METABOLIC</b>					
<b>Rapirosiran</b> (ALN-HSD)	Metabolic Dysfunction-Associated Steatohepatitis (MASH) <sup>1</sup>				
<b>ALN-4324</b>	Type 2 Diabetes Mellitus				
<b>ALN-PNP</b>	Non-Alcoholic Fatty Liver Disease (NAFLD) <sup>3</sup>				
<b>ALN-APOC3</b>	Dyslipidemia <sup>1</sup>				
<b>ALN-CIDEB</b>	Metabolic Dysfunction-Associated Steatohepatitis (MASH) <sup>1</sup>				
<b>NEUROLOGIC</b>					
<b>Mivelsiran</b> (ALN-APP)	Cerebral Amyloid Angiopathy (CAA) <sup>4</sup>				
<b>Mivelsiran</b> (ALN-APP)	Alzheimer's Disease <sup>4</sup>				
<b>ALN-HTT02</b>	Huntington's Disease <sup>5</sup>				
<b>ALN-SOD</b>	SOD1 Amyotrophic Lateral Sclerosis (ALS) <sup>3</sup>				
<b>OTHER</b>					
<b>Cemdisiran</b> (+/- Pozelimab)	Geographic Atrophy <sup>1</sup>				
<b>Elebsiran</b> (+Tobevibart)	Hepatitis D Virus Infection <sup>1</sup>				
<b>Elebsiran</b> (+Tobevibart +/- PEG-IFN-α)	Hepatitis B Virus Infection <sup>1</sup>				
<b>ALN-BCAT</b>	Hepatocellular Carcinoma				
<b>ALN-ANG3</b>	Healthy Volunteers <sup>1</sup>				
<b>ALN-F1202</b>	Healthy Volunteers <sup>1</sup>				

<sup>1</sup> Out-licensed with milestones and/or royalties

<sup>2</sup> Partnered, Alnylam-led development with US profit split and milestones/royalties ex-US

<sup>3</sup> Partner-led with profit split

<sup>4</sup> Product developed as part of a collaboration with Regeneron

<sup>5</sup> Partnered, Alnylam-led with profit split